Geron Corp (GERN) Share Price

GERN. 10 day hourly

Heavy accumulation 😆

LC2020. Posting Paid trash 24/7 is his very proud way of living...

SMH,,,, KARMIC Trap....

I agree, that is why I keep adding. product approved with great results. Just waiting for the true breakout 😃

Grrrrrrrron, as usual.  Here's hoping for some real sp traction in '25! 

Yup, foresure...I forgot that one!

Agree also there might be some selling for tax purposes before year end

With volume reaching 25M today, I believe it is a combo of weak hands getting shaken out, shorts taking advantage of the dip and possibly some tutes re-ajusting accts for year end. Could see more volatility next week. IMO, GERN is a great buy at the $3.50 level, in a few weeks we should hear about EU approval,and 2025 should be a banner year for revs and profits!

EOD will tell a lot about future months. Are shortie's covering or does someone know of a negative news release coming. Time will tell!

Added another 4500 @ $3.53, now hold 27,500 @ $4.01. will be my relocation to warmer weather living 😆

I agree you are

2.6 million traded after hours ending with $3.97

Hahahahahahahaha!!! What a joke

A question to the board...

As owner of Halozyme shares, the Geron patent filing posted below, popped up looking at Halozyme patents.

Was wondering if anyone has heard of Geron working with Halozyme to develop SC injection of Rytelo?

Was going to listen to the Evercore presentation tomorrow to hear if they mention anything.

Thanks, SR

"Subcutaneous telomerase inhibitor compositions and methods for using same "

Ihttps://patents.google.com/patent/US20220168403A1/en

The filing has been rejected twice, so not sure if it future, but is does show interest in SC injection.

Sure is nice days that the price of geron goes up or stays the same we don’t have to hear the rantings of Jethro Bodines buddy

RA Capital

>>The shares reported herein for the Reporting Persons represent (i) 32,285,755 shares of Common Stock held directly, and (ii) 31,033,798 shares of Common Stock that the Reporting Persons beneficially own based on the right to acquire, upon the exercise of Pre-Funded Warrants. The Pre-Funded Warrants contain a provision (the “Beneficial Ownership Blocker”) which precludes the exercise of the warrants to the extent that, following exercise, the Reporting Person, together with its affiliates and other attribution parties, would own more than 9.99% of the Common Stock outstanding. The Reporting Person is currently prohibited from exercising the warrants to the extent that such exercise would result in beneficial ownership of more than 63,319,553 shares of Common Stock.

Oh my it looks like we and I were correct . Too bad you let a spellcheck changing well to we dissuade getting rid of this crap

Hey it’s the “we I hope hope you read” is back …what have you and Jethro been up to

Not even trump can save this useless pile of trash

Shrugs. LP's got the greatest job in the world.  

Like I said here many times I've been comparing Geron's "By the book" approach to LP's bizarre approach.  Geron is now the clear winner. 

>>"This has been a transformative year for Geron, following our first FDA approval and commercial launch of RYTELO in June. The initial full quarter of product revenue from our U.S. launch exceeded our expectations and demonstrates strong execution as a commercial company.



>>In November 2024, completed synthetic royalty and debt financing transactions to strengthen our cash position and further solidify our balance sheet while providing strategic flexibility to invest in our future. We entered into a synthetic royalty agreement with Royalty Pharma providing $125 million of capital in exchange for tiered royalty payments. We also entered into a 5-year, senior term loan agreement with Pharmakon for up to $250 million, from which we have drawn a first tranche of $125 million, a portion of which was used to fully repay amounts owed under our existing loan with Hercules Capital, Inc. and Silicon Valley Bank ($86.5 million), which has now been terminated, with the ability to borrow another $125 million prior to the end of 2025, subject to specified conditions.

Wow, nice!

Achieved $28.2 million in RYTELO™ (imetelstat) net product revenue in first full quarter of salesReceived $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt

You need to reread your post 7806….quote and “yes this is a cancer cure”…..that’s ok dude I understand …..that’s what happens when you sit next to Jerhro Bodine

You said and I quote “ we I hope hope you read “…...and you talk about first grade education…..bhawhahahahahahahahaha

We I hope hope you read the message I wrote making a complete fool of you over the cure . When you get that first grade education let me know moron .

There he is the basher man…..was expecting to hear from you since the stock is down today …..you must of been bored the last few days when Gern went up a bit ….bhawhahahaahahahaha

This board is doing exactly what it should be doing shutting the hell up … there is no defending this garbage company

It may be a quarter too early for that information.  I hope to hear that few patients are complaining about side effects or stopping treatment.  The revs will then follow.  

28% (n=33 out of 118) of patients taking RYTELO required ZERO red blood cell transfusions for 24 consecutive weeks or more vs 3% (n=2 out of 60) of patients taking placebo

Agreed, should be interesting heading to there, best to us all

Regarding earnings in two weeks…..I want to see increased revenues for rytelo …..that’s key and also and updates on European approval

picked up another 1k@4.03. Might use as swing or hold onto longer. Depending on what the earnings report has to say about their future plane's

Oh wow ! This is done it will be in the twos by mid November. People on this board think they proved me wrong because I jokingly use the word cure . Anyone with a first grade education knows there is no cure for any cancer . What you can’t prove me wrong on is this is a poorly run company with a drug that very few people have a need for .

Grrrrron back in the 3's.  Come on already! 

I haven't heard anything yet, 🤔

Well no news yes….but earnings first week of November…..what about European imetelstat approval?

Sorry 3k @ 4.04, for transparency

Picked up 3k. Massive swing with no news what so ever.

That’s all nice but currently under $4 🤮🫣

"Scotiabank Initiates Geron at Sector Outperform With $6 Price Target"


Geez, this stock never disappoints. Eye rolls.



>>Geron (GERN) has an average buy rating and a price target range of $5.50 to $10, according to analysts polled by Capital IQ.

Bought small shares to flip.

I did prove you wrong no where in Geron website nor info. On imetelstat does the word cure used….nice try though…..stick with bashing

Funny I do not need to prove you wrong , you need to prove me wrong . Oh here is your apology, sorry YOU LOSE! Haha

Oh and spike so there is no hard feeling ….no need to apologize

Hey it’s the market maker basher again…..tell me dude where does geron say that imetelstat CURES cancer…..maybe it says can stop the spread and division of cells….NO where does it uses the word CURE….but nice try anyway….

WOW!!!! Longs should be absolutely irate over this stock …. How many effing years has this been and it cannot even get to 5 after fda approval .

1/4 step forward and then 3 steps back . Total joke yes this is a cancer cure haha

It’s over shorts will win like I have said all along … this is done I told people what a shit company this is

If it goes under 4 it will do a RS within one year .

Everyone's just waiting to see if there's any market penetration. Retail will be the last to know either way.

This company can’t even cure its own cancer . Management